MIRA Pharmaceuticals Advances with Regulatory Green Light for Mira-55, Clearing Path for Clinical Development in Pain Management
MIRA Pharmaceuticals Inc. $(MIRA)$ has announced significant progress in its regulatory journey with the U.S. Securities and Exchange Commission $(SEC.UK)$ finalizing its review of the merger proxy related to MIRA's acquisition of SKNY Pharmaceuticals. With no comments from the SEC, MIRA is now moving toward shareholder approval and the final steps needed to complete the transaction. This acquisition includes SKNY-1, an investigational therapy targeting obesity and nicotine addiction. Additionally, MIRA's proprietary drug candidate, Mira-55, has shown promising preclinical results, matching morphine in pain relief without opioid risks, and has received confirmation from the U.S. Drug Enforcement Administration $(DEA)$ that it is not a controlled substance, facilitating further clinical development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017557), on July 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.